药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件文件(201882322265036.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文比阿培南静脉滴注处方资料(仅供参考)
英文药名:Omegacin For Intravenous Drip Infusion(Biapenem)
中文药名:比阿培南静脉滴注
适合病症:新型广谱抗生素
生产厂家:明治制药
药品介绍
治疗类别名称
碳青霉烯类抗生素配方
有效成分:Biapenem(比阿培南)
新型抗菌药物比阿培南(Biapenem)是由日本Lederle公司和美国氰胺公司开发的注射用1β-甲基碳青霉烯类抗生素,已于2002年3月在日本批准上市,目前正在美国进行二期临床试验。
本品和美罗培南一样,具有抗菌谱广、抗菌活性强的特点。比阿培南对革兰阳性菌、革兰阴性菌(包括耐药的绿脓杆菌)、厌氧菌等均具有较强的抗菌活性;对b-内酰胺酶稳定;对DHP-1的稳定性较伊米培南强。较其他已上市的碳青霉烯类品种,比阿培南肾毒性几乎为零,具有能单独给药;并且无中枢神经系统毒性,不会诱发癫痫发作,能用于细菌性脑膜炎的治疗。
本品对抑制绿脓杆菌和厌氧菌比亚胺培南强2~4倍,抑制耐药绿脓杆菌比美罗培南强4~8倍,对不动杆菌、厌氧菌比头孢他啶有效。
药理作用
本品具有抗菌谱广、抗菌活性强的特点,对革兰阳性菌、革兰阴性菌(包括耐药的铜绿假单胞菌)、厌氧菌等均具有较强的抗菌活性;对革兰阴性菌、铜绿假单胞菌的作用强于亚胺培南,对厌氧菌作用相似,对革兰阳性菌的活性略逊于亚胺培南。对β-内酰胺酶稳定;对肾脱氢肽酶(DHp-1)的稳定性较伊米培南强。较其他已上市的碳青霉烯类品种,本品肾毒性几乎为零,能单独给药;无中枢神经系统毒性,不会诱发癫痫发作,能用于细菌性脑膜炎的治疗。对不动杆菌、厌氧菌比头孢他啶有效。对各种细菌有良好的抗生素后效应。
适应证
用于由葡萄球菌、链球菌、肺炎球菌、肠球菌、明串珠菌属、粪肠球菌、肠杆菌科细菌、假单胞菌属、淋球菌、不动杆菌属、弗氏枸橼酸杆菌、脆弱拟杆菌等引起的感染:慢性呼吸道疾病的二次感染,肺炎、肺部化脓,肾盂肾炎,复杂性膀胱炎,腹膜炎,子宫旁结缔组织炎。
不良反应
不良反应主要为消化道症状与过敏症状,未出现中枢神经症状。临床检验值异常主要是天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)上升,嗜酸性粒细胞增多。
用法用量
成人每天静滴两次,每次0.3g(按比阿培南计,30~60min内滴完)。也可根据年龄、症状适当增减,但日最大剂量不得超过1.2g(按比阿培南计)。 使用时应将其溶解于生理盐水或葡萄糖注射液中。
English name: Omegacin For Intravenous Drip Infusion (Biapenem)
Chinese drug name: biapenem intravenous drip
Suitable conditions: new broad-spectrum antibiotics
Manufacturer: Meiji Pharmaceutical
Introduction of drugs
Treatment category name
Carbapenem antibiotic formula
Active Ingredients: Biapenem
The new antibacterial drug Biapenem is a 1β-methyl carbapenem antibiotic for injection developed by Lederle Corporation of Japan and Cyanamide Company of the United States. It was approved for marketing in Japan in March 2002 and is currently being carried out in the United States. Phase II clinical trial.
This product, like melopenem, has a broad antibacterial spectrum and strong antibacterial activity. Biapene has strong antibacterial activity against Gram-positive bacteria, Gram-negative bacteria (including resistant Pseudomonas aeruginosa), anaerobic bacteria, etc.; stable to b-lactamase; stable to DHP-1 Sex is stronger than imipenem. Compared with other listed carbapenems, it has almost zero nephrotoxicity and can be administered alone; it has no central nervous system toxicity, can not induce seizures, and can be used for the treatment of bacterial meningitis. .
This product is 2 to 4 times stronger than Pseudomonas aeruginosa and anaerobic bacteria, and inhibits drug-resistant Pseudomonas aeruginosa 4 to 8 times stronger than meropenem. It is effective against Acinetobacter and anaerobic bacteria than ceftazidime.
Pharmacological action
This product has the characteristics of broad antibacterial spectrum and strong antibacterial activity. It has strong antibacterial activity against Gram-positive bacteria, Gram-negative bacteria (including resistant Pseudomonas aeruginosa), anaerobic bacteria, etc. The negative bacteria and Pseudomonas aeruginosa were stronger than imipenem, similar to anaerobic bacteria, and slightly less active against gram-positive bacteria than imipenem. Stable to β-lactamase; stable to renal dehydropeptidase (DHp-1) compared to imipenem. Compared with other listed carbapenems, the nephrotoxicity of this product is almost zero, can be administered alone; no central nervous system toxicity, will not induce seizures, can be used for the treatment of bacterial meningitis. It is effective against Acinetobacter and anaerobic bacteria than ceftazidime. Good antibiotic effects on various bacteria.
Indications
For Staphylococcus, Streptococcus, Pneumococcal, Enterococcus, Leuconostoc, Enterococcus faecalis, Enterobacteriaceae, Pseudomonas, Neisseria gonorrhoeae, Acinetobacter, F. faecalis, Infections caused by Bacteroides fragilis, etc.: secondary infection of chronic respiratory diseases, pneumonia, lung suppuration, pyelonephritis, complicated cystitis, peritonitis, connective tissue inflammation of the uterus.
Adverse reactions
Adverse reactions were mainly gastrointestinal symptoms and allergic symptoms, and no central nervous system symptoms. Abnormal clinical test values were mainly aspartate aminotransferase (AST), alanine aminotransferase (ALT), and eosinophilia.
Usage and Usage
Adults are given intravenously twice a day, 0.3g each time (by biapenem, 30 to 60 minutes). It can also be increased or decreased according to age and symptoms, but the maximum daily dose should not exceed 1.2g (according to biapenem). It should be dissolved in physiological saline or glucose injection when used.
--------------------------------------------------------------- 详细处方信息以本药内容附件文件(201882322265036.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |